Exclusive: Australian professor Thomas Borody’s failure to widely declare that he could potentially profit from treatment he is promoting raises ethical concerns
A Sydney gastroenterologist who has been enthusiastically promoting an unapproved Covid-19 treatment, including to Australian politicians and general practitioners, has filed a patent in the US for the same treatment, allowing him to commercialise and profit from it, if approved.
Prof Thomas Borody has been quoted in medical newsletters and publications, and in news outlets including the Financial Review, the Daily Telegraph and the Australian, promoting what he describes as a “triple therapy protocol” to treat and cure Covid-19.
